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Heart rate (HR) variability has been extensively studied in patients surviving an acute
myocardial infarction (AMI).The majority of studies have shown that patients with reduced
or abnormal HR variability/turbulence have an increased risk of mortality within few years
after an AMI. Various measures of HR dynamics, such as time-domain, spectral, and
non-linear measures of HR variability, as well as HR turbulence, have been used in risk
stratiﬁcation of post-AMI patients. The prognostic power of various measures, except of
those reﬂecting rapid R–R interval oscillations, has been almost identical, albeit some
non-linear HR variability measures, such as short-term fractal scaling exponent, and HR
turbulence, have provided somewhat better prognostic information than the others. Abnor-
mal HR variability predicts both sudden and non-sudden cardiac death after AMI. Because
of remodeling of the arrhythmia substrate after AMI, early measurement of HR variabil-
ity to identify those at high risk should likely be repeated later in order to assess the
risk of fatal arrhythmia events. Future randomized trials using HR variability/turbulence as
one of the pre-deﬁned inclusion criteria will show whether routine measurement of HR
variability/turbulence will become a routine clinical tool for risk stratiﬁcation of post-AMI
patients.
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The purpose of this mini-review is to discuss the role of mea-
surement of heart rate (HR) variability in patients after an acute
myocardial infarction (AMI), especially its potential or proven
clinical utility, by itself or in combination with other variables.
Studies will be reviewed that employed a large variety of HR vari-
ability measures, with the majority derived from easily obtainable
24-h recordings.
Clinical utility is, of course, a broad concept. In this review,
we will consider a measure to have clinical utility, if it identi-
ﬁes patients at higher risk of an adverse outcome, differentiates
those with more advanced from those with less advanced disease,
identiﬁes those who would beneﬁt from interventions or identiﬁes
thosewho are beneﬁting fromor being harmed by an intervention.
HR variability has been applied in a huge number of studies. We
have chosen to limit our review to main studies focusing on clini-
cal application of HR variability measurements from 24-h Holter
recordings in patients who have survived an AMI.
BACKGROUND FOR ABNORMAL HR VARIABILITY
Heart rate variability is a term that encompasses a large num-
ber of measures of different types that have been described in
details in other articles of this Special Topic of the journal. Time-
domain measures reﬂect “how much” HRV there is. In general,
if such measures are extremely low, it can be assumed that there
is true autonomic dysfunction, but higher values for these vari-
ous measures could reﬂect more healthy autonomic function or
an unhealthy, highly irregular HR pattern (erratic rhythm). Fre-
quency domain measures have the same properties. Extremely
low values are associated with a lack of autonomic modulation
of HR, but higher values, without examination of their under-
lying organization using power spectral plots or other graphical
methods, cannot be assumed to reﬂect better HR variability. Non-
linear measures like the short-term fractal scaling exponent and
the power–law slope, appear to better differentiate between healthy
and unhealthy organization of the heart’s rhythm and have proved
to bemore sensitive for risk stratiﬁcation that some of the standard
measures (Bigger et al., 1996; Huikuri et al., 2000). HR turbu-
lence, which was covered recently in detail (Bauer et al., 2008),
also appears to be sensitive to autonomic dysfunction, especially
to impaired baroreﬂex function. It is likely that the optimal charac-
terization of normal and abnormal HR variability would be based
on a combination of these different HR variability parameters
rather than on a single one.
PROGNOSTIC SIGNIFICANCE OF HR VARIABILITY AFTER AMI
The prognostic signiﬁcance of HR variability has been extensively
studied in patients who have survived anAMI. Table 1 summarizes
the results of main studies assessing the prognostic signiﬁcance of
HR variability measurements from 24-h recordings. As early as
Wolf et al. (1978) showed that patients with a low magnitude of
short-term HR variability (no sinus arrhythmia on 30 consecu-
tive R–R intervals on admitting ECG) had a poor prognosis after
AMI. In the late 1980s, the multicenter post-infarction project
(MPIP) conﬁrmed the predictive value of reduced HRV by mea-
suring 24-h SD of N–N intervals (SDNN) over 24 h followingAMI
(Kleiger et al., 1987). Adjustment for covariates did not explain
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Table 1 | Summary of main studies assessing the prognostic significance of heart rate variability after acute myocardial infarction.
Study HRV
measurement
Number of
patients
Mean follow
up time
Primary
endpoint
Main results Comment
Kleiger et al. (1987) SDNN 808 34months All-cause
mortality
Increased mortality, if
SDNN<50ms
Landmark study
Bigger et al. (1992) Frequency
domain measures
715 2.5 years All-cause death,
cardiac death,
arrhythmic death
All frequency domain
measures of HRV
predicted an increased
risk of primary endpoint
VLF spectral power was
the strongest predictor
Bigger et al. (1993) Frequency
domain measures
331 3 years All-cause
mortality
All frequency domain
measures predicted the
risk of primary endpoint
Holter recording were
performed 1 year after
AMI
Fei et al. (1996) SDNN and HRV
index
700 1 year All-cause
mortality
Geometric HRV index
predicted mortality
better than SDNN
Bigger et al. (1996) Power–law
behavior
715 3 years All-cause
mortality
Power–law regression
between log(power)
and log(frequency)
predicted mortality
Power–law regression
analyzed from ULF and
VLF spectral areas
La Rovere et al. (1998) SDNN 1284 21months Cardiac death and
non-fatal cardiac
arrest
SDNN<70ms
predicted increased
cardiac mortality
Multicenter study
Huikuri et al. (2000) Spectral, fractal
and time-domain
measures
446 685 days All-cause
mortality
Short-term fractal
scaling exponent was
the most powerful
predictor of mortality
Post-AMI patients with
depressed ejection frac-
tion
Mäkikallio et al. (2005) Spectral, fractal
and, time-domain
measures
2130 1012days Sudden cardiac
death,
non-sudden
cardiac death
All HRV measures
predicted sudden and
non-sudden cardiac
death
HRV predicted equally
both sudden and non-
sudden cardiac death.
Largest HRV study
Stein et al. (2005) Spectral, fractal,
and time-domain
measures
740 362 days All-cause
mortality
Fractal measures
predicted all-cause
mortality
Short-term fractal scal-
ing exponent was more
powerful predictor than
other HRV measures
Perkiömäki et al. (2008) Spectral, fractal
and time-domain
measures
675 30months Non-fatal
coronary events
Several measures of
HRV predicted primary
endpoint
Huikuri et al. (2009) Spectral, fractal
and time-domain
measures
312 2 years ECG documental
VT or VF
Many HRV measures
predicted the primary
endpoint
VLF power was the
strongest predictor
Erdogan et al. (2008) SDNN 412 4.3 years All-cause
mortality
SDNN<50ms
predicted mortality
Positive predictive power
of SDNN was low
AMI, acute myocardial infarction; ECG, electrocardiogram; HRV, heart rate variability; SDNN, SD of N–N intervals; ULF, ultra-low frequency; VF, ventricular ﬁbrillation;
VLF, very-low frequency; VT, ventricular tachycardia.
this association. Other studies (including a reanalysis of MPIP)
have shown that spectral measures of HR variability, mainly the
very-low and low frequency spectral components, are reduced in
survivors of AMI and that decreased values are associated with an
increased risk of all-cause mortality (Bigger et al., 1992).
Because accurate Holter scanning is relatively labor intensive,
the group at St. George’s hospital in London experimented with
global, geometric indices of HR variability (HR variability index)
that were derived from the histogram of N–N intervals (Malik
et al., 1989). Decreased values for these measures were also found
to be associated with higher risk of mortality (Fei et al., 1996). In
addition, this group suggested that markedly reduced SDNN for
a single, stable 5-min period could pre-select patients in whom
24-h Holter recordings using geometric methods would provide
signiﬁcant risk stratiﬁcation.
The autonomic tone and reﬂexes after myocardial infarction
(ATRAMI) trial was a multicenter observational study performed
about 10 years after MPIP. The ATRAMI investigators conﬁrmed
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that reduced 24-h SDNN (<70 ms in this case) is associated with
an increased mortality during 21 months of follow up (La Rovere
et al., 1998). Furthermore, the combination of low SDNN and
left ventricular ejection fraction <35% carried a high risk of
mortality.
Early studies focused on measurement of HR variability rel-
atively early after AMI. Measures of HR variability appeared to
be more depressed at the early phase of AMI with substantial
improvement during recovery (Jokinen et al., 2003). Despite this
autonomic recovery, measurement of HR variability has been
shown to yield similar prognostic informationwhen the 24-hHRV
measurements were performed late after AMI (Bigger et al., 1993;
Jokinen et al., 2003).
The post-MI studies performed in the 1980s and 1990s used 24-
h time and frequency domain as well as geometric measures of HR
variability for risk stratiﬁcation of patients after AMI. Although
all statistical, geometrical, and spectral measures of HR variability
differ in their manner of computation and analysis, these methods
are fundamentally based on moment statistics and describe the
magnitude of HR variability or of its underlying components. It
is therefore not surprising that most of these measures that have
been shown to have prognostic value have relatively close mutual
correlation, and that there are only minor differences in prognos-
tic power between them. It must be kept in mind though that
measures of beat-to-beat HR variability which are supposed to
reﬂect respiratory related vagal control of HR (HF power, pNN50,
rMSSD) have rarely shown a strong association with outcome.
This is likely because of the high prevalence of erratic rhythm in
these populations resulting in higher measures for these parame-
ters that do not reﬂect better parasympathetic function. One study
showed that when erratic short-term R–R intervals was excluded
from the analysis, HR variability related to respiratory cycles pre-
dicted sudden cardiac death even better than the standard HR
variability indexes (Peltola et al., 2008).
More recent studies have applied methods based on HR turbu-
lence, non-linear dynamic, and maximum deceleration capacity of
R–R intervals, which provide very different and perhaps comple-
mentary information on HR dynamics compared to traditional
statistical methods (Mäkikallio et al., 2002; Bauer et al., 2006,
2008). Methods based on non-linear dynamics and HR turbulence
have provided somewhat better prognostic information than that
obtained by traditional methods (Bauer et al., 2006, 2008; Perk-
iömäki et al., 2008). In particular, decreased short-term fractal
scaling exponent by the DFA method (called DFA1 or α1), a mea-
sure of greater randomness in HR patterns, has turned out to be
a powerful non-linear index in risk stratiﬁcation, a more power-
ful prognostic tool than other HR variability indexes in post-AMI
populations (Huikuri et al., 2000; Mäkikallio et al., 2002). In the
DIAMOND-MI trial, reduced short-term fractal scaling exponent
identiﬁed post-AMI patients at a relative high risk of mortality
and was more strongly related to outcome than traditional time
and frequency domain measures (Huikuri et al., 2000). More-
over, reduced scaling exponent was related to both arrhythmic and
non-arrhythmic mortality (Huikuri et al., 2000). In another study
of consecutive patients with acute MI, both reduced short-term
fractal scaling exponent and power–law slope were independently
associated with recurrent non-fatal coronary events (Perkiömäki
et al., 2008). Another measure of increased randomness of HR
patterns, such as the ratio of the axes of a Poincare plot ﬁtted to
the plot of each N–N interval vs. the next, also predicted mortality
in the CAST trial (Stein et al., 2005). Patients in the CAST were
at variable times post-MI but were selected for having signiﬁcant
ventricular arrhythmias.
One study in the era of modern therapy showed a very-low
incidence of severely depressed HR variability (SDNN <50 ms;
Erdogan et al., 2008). All patients in the study were treated
with direct percutaneous coronary angioplasty within 12 h of
their event. Although the 4-year survival was signiﬁcantly higher
in the low SDNN group, the positive predictive value was low,
suggesting that the predictive power of HR variability may not
be as high as earlier in patients receiving optimal medical and
revascularization therapy. However, results were based on tradi-
tional time-domain HR variability measures and there was no
report of results for non-linear measures or HR turbulence in this
population.
HR VARIABILITY AS A PREDICTOR OF ARRHYTHMIC
EVENTS/SUDDEN CARDIAC DEATH
The studies assessing the prognostic power of HR variability after
AMI have usually used all-cause mortality as the primary end-
point (see Table 1). Some studies, using various deﬁnitions of
arrhythmic events in their designs, have suggested that reduced
or altered HR variability may be speciﬁcally related to arrhythmic
events and sudden cardiac death. However, the clinical applica-
bility of measurement of HR variability as a predictor of fatal
arrhythmic events was challenged in a randomized prophylactic
implantable cardioverter-deﬁbrillator (ICD) trial, the deﬁbrillator
in AMI trial (DYNAMIT) which, however, used reduced SDNN
combined with reduced left ventricular ejection fraction mea-
sured early (within 2 weeks) after AMI as an inclusion criterion
for the trial. The trial could not show any mortality beneﬁt from
ICD therapy in these presumably high risk patients (Hohnloser
et al., 2004). The more recent multicenter cardiac arrhythmias
and risk stratiﬁcation after myocardial infarction (CARISMA)
study showed that reduced HR variability measured relatively late
(6 weeks after AMI) rather than early after AMI, especially the
very-low frequency spectral component, was the most powerful
index among many other non-invasive risk markers in predicting
the fatal or near-fatal arrhythmic events diagnosed by implantable
arrhythmia devices (Huikuri et al., 2009). A further sub analysis of
the CARISMA and another recent similar study (Risk estimation
after infarction, non-invasive evaluation, REFINE) study con-
ﬁrmed that HR variability and HR turbulence yield more powerful
prognostic information for arrhythmic events when measured late
(6–10 weeks after AMI) rather than early (within 2 weeks) after
AMI in the current treatment era (Huikuri et al., 2010). Thus
the lack of recovery from reduced autonomic function after AMI
was a stronger predictor of adverse events than decreased auto-
nomic function early after AMI. A large study including more than
2000 post-AMI patients (FINGER-study) showed that reducedHR
variability and HR turbulence predicted sudden cardiac death bet-
ter among those with a left ventricular ejection fraction >40%
than in those with ejection fraction <40% (Mäkikallio et al.,
2005).
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HR VARIABILITY AS A PREDICTOR OF NON-SUDDEN
CARDIAC DEATH
Observational studies using various end-points have shown that
reduced HR variability also predicts non-sudden cardiac death.
The largest study in this ﬁeld showed that reduced HR variabil-
ity/turbulence is in fact a stronger predictor of non-sudden than
sudden cardiac death (Mäkikallio et al., 2005). In this study, the
majority of patients were treated according to current guide-
lines, i.e., with primary coronary interventions, beta-blocking
medication, and angiotensin converting enzyme inhibitors.
Considered together, the available data show that abnormal HR
variability, measured by various time and frequency domain mea-
sures, non-linear measures, and turbulence/deceleration capacity
measures from 24-h R–R interval recordings is a general risk
marker for common modes of cardiac death: arrhythmic, vascular,
and hemodynamic afterAMI.HRvariability/turbulencemeasured
early after AMI seems to provide more powerful information on
the risk of early non-sudden cardiac death, especially due to pro-
gressive heart failure. Because of remodeling of the arrhythmia
substrate after AMI, early measurement of HR variability to iden-
tify those at high risk of early mortality should likely be repeated
later in order to assess the true risk of fatal or near-fatal arrhythmia
events.
Often forgotten, however, in this focus on risk stratiﬁcation, is
the negative predictive value of HR variability measures. Patients
with normal HR variability measures, even if they are post-MI,
are at very-low risk of mortality. However, as has been found with
other non-invasive risk markers, the positive predictive accuracy
and sensitivity of abnormal HR variability for adverse outcomes
has remained low in most observational studies. The sensitivity,
speciﬁcity, and predictive values of HR variability in predicting
future events depend partly on deﬁning the cutoff points of abnor-
mal HR variability measures. The cutoff points vary between the
studies and depend on the study populations, such as post-AMI
patients with and without heart failure, usage of beta-blocking
medication etc., which inﬂuence the HR variability measures, and
there is no universal consensus on the ideal cutoffs for different
measures. Age and presence of diabetes and even clinical depres-
sion are other factors inﬂuencing HR variability and should be
considered in deﬁning the cutoff of abnormal measures. HR vari-
ability has been combined with other risk markers in order to
improve risk stratiﬁcation in some studies. The problem with
combining various risk markers, however, is the overall loss of
sensitivity despite an improved positive predictive accuracy.
EFFECT OF INTERVENTIONS ON HR VARIABILITY
Finally, little is known about the effect of interventions on
HR variability in post-AMI patients and about whether inter-
ventions that are associated with improvements in HR vari-
ability are associated with better outcomes or vice versa. One
intervention, coronary artery bypass surgery (CABG) is associated
with markedly decreased HR variability which slowly improves
over weeks and months (Stein et al., 2004). It is likely that any pre-
dictive value for long-term outcomes contained in traditional time
and frequency domain HR variability is lost once the patient has
undergone CABG surgery. However, two studies have shown that
measurements of non-linear HRV parameters after CABG surgery
did identify those at higher risk of a complicated post-surgical
course (Laitio et al., 2000; de Godoy et al., 2009). Only one trial,
the BHAT (Beta-Blocker Heart Attack Trial) examined change in
HR variability with therapy and the subsequent relationship of HR
variability to mortality (Lampert et al., 2003). In BHAT, patients
randomized to propranolol had a signiﬁcantly greater increase in
HF power at 6-weeks and after 21 months of follow up, higher
HR variability at 6 weeks and assignment to the beta-blocker arm
were independent predictors of a combined endpoint. On the
other hand, anti-arrhythmic therapies that proved to be associated
with reduced survival have been associated with negative effects
on HR variability. In a meta-analysis of the effect of pharmaco-
logic, behavioral, and exercise strategies on HR variability, Nolan
et al. (2008) concluded that these secondary preventive strategies
have a moderate but signiﬁcant positive effect on HR variabil-
ity. However, none of the large-scale studies on post-MI patients
conducted so far have shown that improvement of HR variability
by any of the therapeutic interventions would be associated with
better outcome.
FUTURE CHALLENGES AND RECOMMENDATIONS
Future research in this ﬁeld should focus on randomized trials that
take into consideration the timing of HR variability/turbulence
measurement after AMI in their study designs. Information from
such trials may identify the populations in which the clinical
applicability of routine measurement of HR variability is war-
ranted. Measurement of the evolution of HR variability over time
in association with prescribed therapies, perhaps on an individ-
ual basis, may also add to the clinical value of HR variability.
Measures of HR variability should be combined with other clin-
ical risk variables or biomarkers, in future studies to create risk
scoring for post-AMI patients based on multiple risk factors. Cur-
rently,ongoing study (REFINE–ICD),where patientswith reduced
HR turbulence, abnormal time-domain T-wave alternans, and
left ventricular ejection fraction between 35 and 50% measured
2–14 months after AMI are being randomized to ICD therapy
(ICD) and standard therapy (personal communication). If mortal-
ity beneﬁt is observed in the ICD arm of this trial, measurement
of HR turbulence will become a routine clinical tool for a large
number of post-AMI patients. Before the completion of the trial
or other similar trials, patients with low HR variability/turbulence
after AMI should receive the best available medical and invasive
therapy, rehabilitation, and follow-up, even if routine measure-
ments of HR variability/turbulence cannot yet be recommended
in clinical practice guidelines.
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